regulatory
confidence high
sentiment neutral
materiality 0.50
Enveric Biosciences regains Nasdaq equity compliance; bid price deficiency remains
Enveric Biosciences, Inc.
- Received Nasdaq letter on May 21, 2024 confirming compliance with minimum stockholders' equity requirement.
- Stockholders' equity as of March 31, 2024 was $6,481,856.
- Minimum bid price deficiency under Nasdaq Rule 5550(a)(2) remains outstanding.
- Company intends to monitor bid price and consider available options to resolve the deficiency.